Levi Strauss & Co. vs Merck & Co., Inc. — how do they compare? Levi Strauss & Co. trades at $22.73 (market cap $8.75B), while Merck & Co., Inc. trades at $130.29 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 36.8× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| LEVI | MRK | |
|---|---|---|
Market Cap | $8.75B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $131.84 |
52-Week Low | $17.92 | $77.60 |
Enterprise Value | $10.07B | $368.53B |
Dividend Yield | 2.81% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Trailing returns across standard periods
Latest headlines on both assets
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →